ArticleMolecules (Basel, Switzerland)2016
Inhibition of Urease by Disulfiram, an FDA-Approved Thiol Reagent Used in Humans.
Article in Molecules (Basel, Switzerland), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 42 citations in OpenAlex.
- Urease inhibitors: current advances, therapeutic potentials, and clinical challenges.Future medicinal chemistry · 2026Review
- Review
- Review
- Article
- Potential Inhibitors Targeting Papain-Like Protease of SARS-CoV-2: Two Birds With One Stone.Frontiers in chemistry · 2022Review
- FDA-approved thiol-reacting drugs that potentially bind into the SARS-CoV-2 main protease, essential for viral replication.Journal of biomolecular structure & dynamics · 2021Article
- Targeting SARS-CoV-2 viral proteases as a therapeutic strategy to treat COVID-19.Journal of medical virology · 2021Review
- Therapeutic approaches against coronaviruses acute respiratory syndrome.Pharmacology research & perspectives · 2021Review
- Ebselen, Disulfiram, Carmofur, PX-12, Tideglusib, and Shikonin Are Nonspecific Promiscuous SARS-CoV-2 Main Protease Inhibitors.ACS pharmacology & translational science · 2020Article
- COVID-19 therapy: What weapons do we bring into battle?Bioorganic & medicinal chemistry · 2020Article
- Ebselen, disulfiram, carmofur, PX-12, tideglusib, and shikonin are non-specific promiscuous SARS-CoV-2 main protease inhibitors.bioRxiv : the preprint server for biology · 2020Article
- The Repurposed Drug Disulfiram Inhibits Urease and Aldehyde Dehydrogenase and PreventsAntimicrobial agents and chemotherapy · 2019Article
- Coptisine-induced inhibition of Helicobacter pylori: elucidation of specific mechanisms by probing urease active site and its maturation process.Journal of enzyme inhibition and medicinal chemistry · 2018Article
- Recent advances in design of new urease inhibitors: A review.Journal of advanced research · 2018Review
- Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes.Antiviral research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Urease is a nickel-dependent amidohydrolase that catalyses the decomposition of urea into carbamate and ammonia, a reaction that constitutes an important source of nitrogen for bacteria, fungi and plants. It is recognized as a potential antimicrobial target with an impact on medicine, agriculture, and the environment. The list of possible urease inhibitors is continuously increasing, with a special interest in those that interact with and block the flexible active site flap. We show that disulfiram inhibits urease in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.